We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$89.4M
Cap. Flow %
4.5%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Consumer Staples 0.19%
3 Consumer Discretionary 0.06%
4 Energy 0.04%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
101
Edwards Lifesciences
EW
$52.3B
$719K 0.04%
+18,264
New +$667K
INCY icon
102
Incyte
INCY
$26B
$707K 0.04%
5,619
– –
ZSAN
103
DELISTED
Zosano Pharma Corporation
ZSAN
$705K 0.04%
714
– –
STLA icon
104
Stellantis
STLA
$19.4B
$659K 0.03%
62,248
– –
HRC
105
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$631K 0.03%
7,930
– –
ACOR
106
DELISTED
Acorda Therapeutics
ACOR
$626K 0.03%
+265
New +$525K
CNC icon
107
Centene
CNC
$32.3B
$617K 0.03%
15,452
– –
AKAO
108
DELISTED
Achaogen Inc
AKAO
$599K 0.03%
27,551
+4,055
+17% +$92.6K
VNDA icon
109
Vanda Pharmaceuticals
VNDA
$323M
$591K 0.03%
36,232
– –
MOH icon
110
Molina Healthcare
MOH
$10.6B
$563K 0.03%
+8,140
New +$499K
RACE icon
111
Ferrari
RACE
$72.6B
$533K 0.03%
6,200
– –
TARA icon
112
Protara Therapeutics
TARA
$231M
$518K 0.03%
8,353
– –
ICLR icon
113
Icon
ICLR
$13B
$507K 0.03%
+5,187
New +$459K
SYNH
114
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$499K 0.03%
+8,532
New +$443K
CDTX
115
DELISTED
Cidara Therapeutics
CDTX
$465K 0.02%
3,106
-38,212
-92% -$5.28M
DPLO
116
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$454K 0.02%
+30,658
New +$511K
PTLA
117
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$442K 0.02%
7,870
-50,000
-86% -$2M
VYGR icon
118
Voyager Therapeutics
VYGR
$213M
$310K 0.02%
+34,604
New +$348K
CUTR
119
DELISTED
Cutera, Inc.
CUTR
$310K 0.02%
11,981
-12,000
-50% -$262K
GRCE
120
Grace Therapeutics
GRCE
$45.2M
$247K 0.01%
3,887
– –
ONSIW
121
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$80K ﹤0.01%
462,500
– –
ONSIZ
122
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$42K ﹤0.01%
462,500
– –
CDMO
123
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$15K ﹤0.01%
3,476
– –
ABBV icon
124
AbbVie
ABBV
$465B
– –
-380
Closed -$25K
ABT icon
125
Abbott
ABT
$197B
– –
-415
Closed -$18K
3 4
5
6 7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $89.4M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.